Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
Labrie
F
F
Department of Molecular Endocrinology, Laval University Medical Center, Quebec, Canada.
Dupont
A
A
Cusan
L
L
Bélanger
A
A
Giguère
M
M
Labrie
C
C
Lacourcière
Y
Y
Monfette
G
G
Emond
J
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D013196:Dihydrotestosterone / Q000032:analysis; D005485:Flutamide / Q000008:administration & dosage; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011467:Prostate / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; C019176:Tryptal; D005485:Flutamide